Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer


You May Also Like

2X Oncology to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the ...

Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference

DURHAM, N.C., June 08, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology ...